SOUTH SAN FRANCISCO, Calif., May 1 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced the filing of a new shelf registration statement with the Securities and Exchange Commission (SEC) pursuant to Rule 415 under the Securities Act of 1933, as amended. The new shelf registration statement is being filed to replace the shelf registration statement initially filed by the company on December 23, 2002, which was fully utilized following the completion of a $60 million registered direct offering on April 11, 2007. After the new registration statement becomes effective, the company may periodically issue up to $150 million of securities at its discretion. The company expects from time to time to use the net proceeds from potential future transactions carried out under the shelf registration statement for general company purposes, including research and development expenses and to provide financing as may be needed from time to time for Phase 3 trials of the company’s lead product GVAX(TM) immunotherapy for prostate cancer. While the company does not have any present intention to use the shelf registration statement under current market conditions, the shelf registration statement is intended to give Cell Genesys greater flexibility to take advantage of favorable market conditions as they may arise and to complement funding from potential corporate collaborations.
A registration statement on Form S-3 filed by Cell Genesys relating to these securities was filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Any offering may be made only by means of prospectus and a related prospectus supplement. A copy of the registration statement on Form S-3 filed by Cell Genesys may be obtained at the SEC’s website at http://www.sec.gov, at the company’s website at http://www.cellgenesys.com or from the company by contacting investor relations at the phone number listed above or by submitting a written request to the company at 500 Forbes Boulevard, South San Francisco, California 94080.
Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company’s website at http://www.cellgenesys.com.
Statements made herein about the company, other than statements of historical fact, including statements about the company’s potential financings and collaborations, results and timing of clinical trials and preclinical programs, and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation and availability of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company’s Annual Report on Form 10-K for the year ended December 31, 2006 filed on March 1, 2007 as well as Cell Genesys’ reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.
Statements made herein about the company, other than statements of historical fact, including statements about the company’s potential financings and collaborations, results and timing of clinical trials and preclinical programs, and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation and availability of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company’s Annual Report on Form 10-K for the year ended December 31, 2006 filed on March 1, 2007 as well as Cell Genesys’ reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.
Contact: Ina Cu
Investor Relations 650-266-3200
Cell Genesys, Inc.
CONTACT: Ina Cu, Investor Relations of Cell Genesys, Inc., +1-650-266-3200
Web site: http://www.cellgenesys.com/
